Alpha Cognition Inc. announced that it has cancelled an aggregate of 4,655,000 incentive stock options with exercise prices ranging from $0.64 CAD to $1.05 CAD. The board of directors has also approved the grant of options totaling 4,655,000 to certain directors, officers, employees and consultants of the company at $0.28 per share, with vesting in monthly installments over either an 8 month, 18 month or 24 month term. The company intends to seek the requisite shareholder approval at its next annual general meeting. The option cancellation and new grant is intended to maintain appropriate incentives as necessary to retain valued team members.

Alpha Cognition Inc. is a Bristol Investor Relations client and describes itself as a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders.

Read the full press release here: Alpha Cognition Announces Cancelation and Grant of Stock Options